Researchers compare the glucagon-like peptide-1 receptor agonists liraglutide, semaglutide, and dulaglutide in more than 21,000 U.S. veterans with type 2 diabetes found similar kidney and cardiovascular protection across agents but modest mortality and gastrointestinal safety differences. Liraglutide was associated with lower all-cause mortality than semaglutide or dulaglutide, while dulaglutide carried a reduced risk of gallstones and cholecystitis. All drugs achieved comparable weight loss (approximately 10–12 lb) over 2 years. These real-world findings support class-wide cardiorenal benefits but suggest subtle distinctions that may influence personalized glucagon-like peptide-1 receptor agonist selection as these agents become more broadly available.
Sources:
